Zacks Research Has Negative Outlook for Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Zacks Research lowered their Q1 2026 earnings per share (EPS) estimates for Biogen in a research note issued to investors on Wednesday, March 12th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $3.49 for the quarter, down from their prior estimate of $3.59. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q2 2026 earnings at $4.30 EPS, Q3 2026 earnings at $4.07 EPS, Q4 2026 earnings at $4.09 EPS, FY2026 earnings at $15.96 EPS and FY2027 earnings at $16.84 EPS.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Several other analysts also recently weighed in on BIIB. Scotiabank lowered their price target on shares of Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a research note on Thursday, February 13th. Truist Financial decreased their price target on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Sanford C. Bernstein began coverage on shares of Biogen in a report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Finally, Royal Bank of Canada cut their price target on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, February 13th. Seventeen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Biogen presently has a consensus rating of “Hold” and an average price target of $213.33.

Biogen Stock Performance

NASDAQ BIIB opened at $139.98 on Friday. Biogen has a 52-week low of $128.51 and a 52-week high of $238.00. The company has a fifty day moving average of $143.35 and a 200-day moving average of $165.02. The company has a market capitalization of $20.49 billion, a P/E ratio of 12.51, a P/E/G ratio of 1.51 and a beta of 0.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen in the fourth quarter valued at approximately $25,000. Larson Financial Group LLC lifted its holdings in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 141 shares during the period. Ashton Thomas Securities LLC purchased a new stake in shares of Biogen during the 3rd quarter worth $33,000. Colonial Trust Co SC grew its stake in shares of Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 186 shares during the period. Finally, SRS Capital Advisors Inc. acquired a new position in shares of Biogen during the 4th quarter worth $33,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Insiders Place Their Bets

In related news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now directly owns 11,318 shares of the company’s stock, valued at $1,697,926.36. This represents a 43.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.